- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03771924
Postprandial Response of Individuals to Dietary Inorganic Phosphate
Postprandial Response of Individuals to Dietary Inorganic Phosphate- a Randomized Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It is a monocentric, controlled intervention trial. The study will be carried out in cross-over design. This design was chosen because of a moderately strong individual metabolic response to the test meal.
Two interventions are planned in which the subjects will receive a test meal with phosphate supplement or with placebo in random order on 2 days. Subjects will be randomized to one of the 2 treatment arms.
On the two intervention days (T1 and T2), the subjects are placed a venous indwelling cannula. Immediately after the first blood sample the subjects take the fat and carbohydrate-rich test meal along with 700 mg of phosphorus or a placebo, both in the form of capsules. Phosphorus is administered as sodium phosphate . The placebo used is sodium chloride with equivalent amounts of sodium. The filler should be silica and mannitol. The capsules are made of hard gelatin and dissolve in about 10 minutes. The capsules are taken with 300 ml of water. The verum and placebo capsules are produced by the central pharmacy of the University Hospital.
The test meal consists of a pasta dish with oily tomato sauce. It is freshly prepared by the study staff and packaged airtight in individual portions before being handed out to the subjects. The test meal should be consumed within 10 - 12 minutes. The time is documented by the study staff. The next blood sample is taken immediately after the end of consumption (time 0), all other 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420 and 480 minutes thereafter. All blood samples are taken in a lying position. The first 3 hours after eating the test meal the subjects should spend reclining. In the following 5 hours subjects are free to move in the study center with each patient taking a recumbent position 10 minutes before the next blood draw. Immediately before all blood samples are taken the measurement of blood pressure and pulse is provided for which the opposite arm is to be used. Furthermore the collection of urine samples is provided every hour. Subjects are encouraged to take 200 ml of water every hour on the intervention day. At the end of the intervention, a snack will be provided.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Saxony Anhalt
-
Halle, Saxony Anhalt, Germany, 06120
- Martin-Luther-University Institute of Agriculture and Nutritional Science
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy men and women
- age between 18 and 60 years
- informed consent
- body mass index between 18,5 up to 29,9 kg/m2
- anamnesis without diagnostic findings
Exclusion Criteria:
- Participants with epidermal growth factor receptor (eGFR) < 90 ml/min and chronic kidney disease
- Subjects suffering from vitamin D-deficiency (plasma 25(OH)D < 30 nmol/l)
- Pregnancy or lactation
- Subjects with any acute or chronic diseases (infection, tumor, cardiovascular diseases, respiratory diseases, inflammatory diseases), gastrointestinal diseases, diabetes mellitus type 1 and 2, bone diseases, diseases of the parathyroid gland
- Use of medication
- Use of dietary supplements (minerals)
- Relevant food allergies (wheat protein, tomatoes)
- Weight reduction
- Smokers
- Blood donor in the last 3 months
- Participation in another intervention study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: inorganic phosphate
Experimental intervention: Single dose of orally administered 700 mg inorganic phosphate as sodium phosphate in combination with a standardized meal and blood sampling |
Sodium phosphate
|
Placebo Comparator: Placebo
Single dose of Sodium chloride in combination with a standardized meal and blood sampling
|
Sodium chlorid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postprandial change of plasma phosphate concentration from baseline (0 minute) until 480 minutes
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels of plasma phosphate concentration
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postprandial course of the plasma concentration of: electrolytes (calcium, sodium, potassium, magnesium)
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Postprandial course of the plasma concentration of: phosphate status markers (c-terminal and intact FGF23, parathormone, soluble Klotho (sKlotho), calcitriol)
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Postprandial course of plasma concentration of: cardiovascular risk marker glucose
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Postprandial course of plasma concentration of: cardiovascular risk marker insulin
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Postprandial course of plasma concentration of: cardiovascular risk marker triglycerides
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Postprandial course of plasma concentration of: cardiovascular risk marker cholesterol
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Postprandial course of concentration of: calcification markers dephosphorylated, noncarboxylated matrix Gla protein (dp-ucMGP), fetuin A, osteocalcin, osteoprotegerin) Inflammatory markers (hsCRP and inflammatory cytokines, especially interleukin (IL-1β)
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Activation of NLRP3-inflammasome components (ASC, caspase-1) in isolated peripheral blood monocytes (PBMC) and granulocytes under basal conditions and after stimulation
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
systolic and diastolic blood pressures
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
time course: measurement of blood pressure in mm Hg
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
heart rate
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
time course: measurement of heart rate in beats per minute
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Postprandial course of urine concentrations of electrolytes (phosphate, sodium, potassium, calcium, magnesium) and creatinine
Time Frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Impact of inorganic phosphate on the postprandial levels
|
0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Gabriele Stangl, Prof.Dr., MLU, Institut für Agrar-und Ernährungswissenschaften
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- BMBF WP2A3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Risk Factor
-
University of Southern DenmarkRegion of Southern Denmark; Odense Patient Data Explorative Network; ENIGMA Solutions... and other collaboratorsActive, not recruitingCardiovascular Risk Factor | Risk CommunicationDenmark
-
University of Split, School of MedicineCompletedCardiovascular Risk Factor | Lifestyle Risk ReductionCroatia
-
University Hospital, BrestRecruiting
-
University Hospitals Cleveland Medical CenterRecruitingCardiovascular Risk FactorUnited States
-
Northwestern UniversityNorthShore University HealthSystem; Case Western Reserve University; Shirley... and other collaboratorsCompleted
-
University of ArizonaTerminatedCardiovascular Risk FactorUnited States
-
Penn State UniversityCompletedCardiovascular Risk FactorUnited States
-
Clinique BizetCompleted
-
University Hospital, BrestCompleted
-
University of DelawareCompleted
Clinical Trials on inorganic phosphate
-
University of CopenhagenStine Kristensen; Gita Krüger Mørch; Rizwan Butt; Ditte HansenNot yet recruitingChronic Kidney Disease Requiring Chronic DialysisDenmark
-
University of Sao PauloCompleted
-
University of Sao PauloCompletedPeriodontal Diseases | Bone DiseasesBrazil
-
Swiss Paraplegic Centre NottwilUniversity of ZurichCompleted
-
University of VirginiaActive, not recruitingHealthyUnited States
-
Shannaz Nadia YusharyahyaUnknownSunscreen PersistenceIndonesia
-
University of Texas Southwestern Medical CenterCompletedHypertensionUnited States
-
Taylor's UniversityCompletedHyperphosphatemia | End Stage Renal Disease on DialysisMalaysia
-
The University of QueenslandNational Health and Medical Research Council, Australia; Cambridge University... and other collaboratorsRecruitingKidney Failure, Chronic | HyperphosphatemiaCanada, United Kingdom, Australia, Brazil, New Zealand
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingChronic Lymphocytic LeukemiaUnited States